LINTHICUM, Md. — CARE Pharmacies Cooperative Inc. recently announced the appointment of Sherri Cherman to the 2021 Board of Directors and reappointed Christine Lee-Wilson, and Paul Vitale to serve additional terms. “We are fortunate to have Paul and Christine stay on as Board Members and have Sherri join our team, “said Mike Wysong, Chief Executive
For five of the past six years, Care Pharmacies has earned a place on the National Retail Federation’s Hot 100 list. In this week’s Video Forum, Mike Wysong, the company’s chief executive officer, talks about the reasons behind Care’s robust growth, collaboration among its members, and efforts to bolster sales outside the pharmacy department.
DIR fees are again top of mind for pharmacy operators beginning another year without relief from these “phantom” expenses. At the same time hope springs eternal for retailers looking to broaden affordable and accessible health care offerings when such services from more traditional providers can be out of financial reach for many people. Chains also
LINTHICUM, MD — CARE Pharmacies Cooperative Inc. has named Lionel Phillips and Dean Gruber to its 2019 Board of Directors. Both appointees have been recognized nationally for their continued contributions to community and retail pharmacy. “We are fortunate to add these two dynamic industry veterans to our leadership team”, said Mike Wysong, CEO of CARE Pharmacies.
LINTHICUM, Md. — CARE Pharmacies, a member-owned cooperative of independent community and specialty pharmacies, promoted Wafaa Berrady earlier this month to vice president of finance. In her new role, Berrady will oversee all the chain level financial functions of the growing cooperative drug chain. “Mrs. Berrady has been instrumental in helping CARE Pharmacies serve its customers for
What will the second year of the Trump administration look like? Is the demise of the Affordable Care Act imminent? Will pharmacists get the greater role in health care they have long sought? These are among the questions top chain drug industry executives are pondering as they look to 2018. With spiraling health care costs and
LINTHICUM, Md. — The unique operating model of Care Pharmacies Cooperative has been the key to the company’s record growth, says chief executive officer Michael Wysong. The company’s unique operating structure, he says, allows its members to take full advantage of the logistical and operational efficiencies of the chain while maintaining their uniqueness as independent
LINTHICUM, Md. — Care Pharmacies has promoted Mark Ey to vice president of pharmacy operations. He will lead all chain-level operational functions. “We are very excited to have Mark take on an increased level of responsibility within the drug chain,”stated Michael Wysong, chief executive officer. “Mark’s direct impact on our ability to serve our customers
LINTHICUM, Md. — Care Pharmacies Cooperative Inc. has promoted Mark Ey to vice president of pharmacy operations. The pharmacy co-op said Monday that with the promotion, Ey will oversee all chain-level operational functions. He previously held the title of director of operations and support services. A University of Maryland School of Pharmacy graduate, Ey also
LINTHICUM, Md. — Care Pharmacies Cooperative Inc. has officially launched its proprietary specialty pharmacy network, called Care Connect. The network will serve the cooperative’s member pharmacies as well as independent retail pharmacies. Care unveiled plans for the network last May in announcing its partnership with specialty pharmacy provider Aureus Health Services Inc. Under Care Connect,
LINTHICUM, Md. — Care Pharmacies has extended chief executive officer Michael Wysong’s employment contract for an undisclosed period. During Wysong’s tenure, Care Pharmacies’ sales have increased by more than 300%, and the company has gained recognition by the National Retail Federation. “Care Pharmacies is delighted to have Wysong continue in his current leadership role,” Care
LINTHICUM, Md. — For Care Pharmacies, 2014 was a year of impressive top-line growth while the company continued to focus on infrastructure improvement with a number of technology initiatives. Sales for the year soared 26.6% to $463.3 million, driven largely by the entry into the market of hepatitis C drugs, says chief executive officer Michael